Valuation: Photocure ASA

Market Cap 1.52B 161M 139M 131M 119M 224M 15.4B 227M 1.53B 599M 7.71B 605M 592M 25.64B P/E 2026 *
20x
P/E 2027 * 72.4x
Enterprise Value 1.35B 143M 124M 116M 106M 199M 13.69B 202M 1.36B 532M 6.86B 538M 526M 22.79B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 2.05x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-2.75%
3 months-18.67%
6 months-14.14%
Current year-14.14%
Current year 6.01
Extreme 6.01
7.39
1 year 5.58
Extreme 5.58
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
12.8
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 01/11/2018
Chief Tech/Sci/R&D Officer - 01/08/2021
Human Resources Officer - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/01/2022
Chairman - 27/09/2023
Director/Board Member - 23/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%-.--% - - 161M
-2.25%-0.47%+72.43%+119.36% 1,052B
-0.66%+0.43%+49.01%+50.11% 627B
-0.54%+1.39%+21.88%+63.83% 441B
-1.99%-3.32%+41.98%+34.08% 349B
-1.05%-2.81%+24.22%+34.67% 287B
-2.12%-3.67%-1.09%+3.11% 241B
-0.63%+1.04%+43.03%+59.10% 224B
-1.19%-3.41%-9.18%-52.41% 202B
+0.16%+3.87%+16.25%+73.27% 172B
Average -0.87%+0.43%+28.73%+42.79% 399.46B
Weighted average by Cap. -0.09%+0.32%+41.31%+62.03%

Financials

2026 *2027 *
Net sales 658M 69.74M 60.23M 56.6M 51.48M 96.78M 6.67B 98.37M 663M 259M 3.34B 262M 256M 11.1B 666M 70.59M 60.97M 57.29M 52.1M 97.95M 6.75B 99.57M 671M 262M 3.38B 265M 259M 11.23B
Net income 76.33M 8.09M 6.98M 6.56M 5.97M 11.22M 773M 11.41M 76.9M 30.07M 387M 30.36M 29.7M 1.29B 21M 2.22M 1.92M 1.81M 1.64M 3.09M 213M 3.14M 21.16M 8.27M 107M 8.35M 8.17M 354M
Net Debt -169M -17.9M -15.46M -14.53M -13.21M -24.84M -1.71B -25.25M -170M -66.57M -857M -67.22M -65.76M -2.85B -157M -16.63M -14.36M -13.5M -12.28M -23.08M -1.59B -23.46M -158M -61.84M -796M -62.44M -61.09M -2.65B
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Date Price Change Volume
05/08/26 USD 0.000000 - 27,675
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
56.50NOK
Average target price
79.67NOK
Spread / Average Target
+41.00%

Quarterly revenue - Rate of surprise